Coexistence of HBsAg/Anti-HBs and HBeAg/Anti-HBe in Sudanese Patients with Chronic Hepatitis B Virus Infection: A Cross-Sectional Study

Background: Seroconversion of hepatitis B surface antigen (HBsAg) to hepatitis B surface antibody (anti-HBs) is a
recognized goal of HBV therapy. This dynamic transition responsible for the coexistence of HBsAg and anti-HBs is rarely detected
in clinical cases. However, with vaccination and the use of various antiviral drugs, as well as the development of new medical
technologies, recognizing the coexistence of HBsAg and anti-HBs has become more common. In addition, mutations in viral
genomes, immune status, and human genetic factors may also contribute to such coexistence. The current study was designed to
determine the prevalence of the coexistence of HBsAg and anti-HBs and HBeAg and anti-HBe in CHB patients in Sudan.
Methods and Results: This was a descriptive cross-sectional study conducted in Khartoum state from November 2018
to January 2019. The study included 70 HBV-infected patients who were positive for HBsAg for more than six months. Blood
samples were tested for HBsAg/Anti-HBs and HBeAg/Anti-HBe using Commercial ELISA Kits (Foresight, United Kingdom)
and (PRECHEK, USA). Demographic data were collected using a structured questionnaire, and any antiviral agent and laboratory
results were also recorded for each participant. The current study showed that one case (1.4%) was reactive for the coexistence
of HBsAg/HBsAb and two cases (2.8%) for the coexistence of HBeAg/HBeAb. There was no statistical difference between the
coexistence of HBsAg/HBsAb and HBeAg/HBeAb with age, gender, residence, and treatment status.
Conclusion: Our study indicates that the frequencies of the coexistence of HBsAg/HBsAb and HBeAg/HBeAb among
Sudanese patients with chronic HBV infection were low compared to previous studies in a different population.(International
Journal of Biomedicine. 2023;13(4):281-285.